PSP Research’s Enliven Therapeutics ELVN Stock Holding History

PSP Research’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$355K	Hold	7,000	–	–	0.19%	41
2026 Q1	$274K	Buy	+7,000	New	+$194K	0.19%	61

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

PSP Research's ELVN Position: Q2 2026 in Review

PSP Research held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 7,000 shares worth $355K. The position accounts for 0.19% of the portfolio, ranked #41.

PSP Research first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

PSP Research held 7,000 shares of Enliven Therapeutics worth $355K as of Q2 2026.
PSP Research left its Enliven Therapeutics share count unchanged in Q2 2026.
Enliven Therapeutics made up 0.19% of PSP Research's portfolio in Q2 2026, its #41 holding.
PSP Research first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.